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Abstract
Summary—The association between follicle-stimulating hormone (FSH) and bone density was
tested in 111 postmenopausal women aged 50–64 years. In the multivariable analysis, weight and
race were important determinants of bone mineral density. FSH, bioavailable estradiol, and other
hormonal variables did not show statistically significant associations with bone density at any site.
Introduction—FSH has been associated with bone density loss in animal models and
longitudinal studies of women. Most of these analyses have not considered the effect of weight or
race.
Methods—We tested the association between FSH and bone density in younger postmenopausal
women, adjusting for patient-related factors. In 111 postmenopausal women aged 50–64 years,
areal bone mineral density (BMD) was measured at the lumbar spine, femoral neck, total hip, and
distal radius using dual-energy X-ray absorptiometry, and volumetric BMD was measured at the
distal radius using peripheral quantitative computed tomography (pQCT). Height, weight,
osteoporosis risk factors, and serum hormonal factors were assessed.
Results—FSH inversely correlated with weight, bioavailable estradiol, areal BMD at the lumbar
spine and hip, and volumetric BMD at the ultradistal radius. In the multivariable analysis, no
hormonal variable showed a statistically significant association with areal BMD at any site.
Weight was independently associated with BMD at all central sites (p<0.001), but not with BMD
or pQCT measures at the distal radius. Race was independently associated with areal BMD at all
sites (p≤0.008) and with cortical area at the 33% distal radius (p=0.004).
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Conclusions—Correlations between FSH and bioavailable estradiol and BMD did not persist
after adjustment for weight and race in younger postmenopausal women. Weight and race were
more important determinants of bone density and should be included in analyses of hormonal
influences on bone.
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Introduction
A 2006 study by Sun et al. suggested that high circulating concentrations of follicle-
stimulating hormone (FSH) significantly contributed to the bone loss seen in hypogonadal
mouse models [1]. Several basic science and clinical studies have offered further support for
this hypothesis. Liu et al. demonstrated that an FSH inhibitor had protective effects on
alveolar bone resorption [2], and Rendina identified an allele of the FSH receptor that was
associated with lower bone mineral density (BMD) in postmenopausal women aged 50–75
years [3]. A 2006 longitudinal cohort study of pre- and perimenopausal women showed that
bone turnover and spine and hip bone mineral density losses were more strongly associated
with longitudinal FSH changes than with estradiol (E2) or other hormonal variables [4]. In
2008, Riggs et al. published a prospective, population-based assessment of rates of bone loss
at multiple skeletal sites measured by quantitative computed tomography (QCT) of the
lumbar spine and peripheral QCT (pQCT) of the distal radius and tibia [5]. In
postmenopausal women who were not being treated with estrogen, selective estrogen
receptor modulators, or bisphosphonates, multiple significant correlations of FSH,
bioavailable E2, and bioavailable testosterone with both cortical and trabecular bone loss
were found at all sites studied. A cross-sectional study of 699 healthy Chinese women found
that serum FSH and LH levels were significantly negatively correlated with areal BMD [6].
Collectively, the above studies suggested that FSH might have a role independent of
estrogen in controlling bone mass and might be a useful predictor of osteoporosis risk.
However, other studies have shown opposing findings and a more complex picture. Gao et
al. demonstrated lack of a direct effect of FSH in causing bone loss in the FSH receptor null
mouse [7]. Similarly, in 2010, Drake et al. demonstrated in a prospective study that GNRH
suppression of FSH secretion in postmenopausal women increased levels of bone resorption
markers; they concluded that FSH does not regulate bone resorption [8]. In a 2004 cross-
sectional study of women under age 40, Devleta et al. found greater bone loss in
hypergonadotropic amenorrheic women than in hypogonadotropic amenorrheic women [9].
Importantly, they found a positive correlation between BMI and lumbar spine bone density
(P=0.025) in the amenorrheic women, and that BMI was more strongly associated with bone
density (P=0.032) than duration of amenorrhea. Although the authors speculated about a
possible direct effect of FSH on bone metabolism, the lower BMI of the hypergonadotropic
amenorrheic women compared with the hypogonadotropic group likely influenced the bone
density findings. The conflicting results among these analyses warrant a more thorough
investigation of potential confounding factors such as weight in the apparent association
between FSH and low bone density.
We conducted a cross-sectional study to test associations between serum FSH and measures
of bone strength in 111 postmenopausal women aged 50–64 years, some with past or current
hormone use. The study population represented patients too young for routine BMD
screening, but at an appropriate age for osteoporosis risk factor assessment. This age range
of women has also been exposed to persistently high FSH concentrations for years, and so
would be more likely than premenopausal women to show low bone density if FSH is
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associated with bone loss. In addition to dual-energy X-ray absorptiometry (DXA), we used
pQCT at the distal radius to detect differences in the trabecular and cortical bone
compartments that might be missed by routine clinical imaging techniques. We
hypothesized that after adjustment for anthropomorphic and demographic measures,
endogenous and exogenous estrogen, and other hormonal factors that might affect bone
density, higher serum FSH concentrations would be associated with lower DXA and distal
radial pQCT bone density measures. Lack of such findings could indicate patient-related
variables such as weight and race provide important information in analyses of hormonal
influences on bone in postmenopausal women.
Methods
Study participants
Participants were 111 community-dwelling postmenopausal women aged 50–64 years of
mixed ethnic background, recruited between 2005 and 2010 from appointment rosters of
university-based primary care clinics or from the community by university e-mail listservs,
posters, and referrals by past study participants. Postmenopausal status was defined as the
absence of menstrual bleeding or spotting for >12 consecutive months prior to eligibility
screening. We included past or current hormone users because these women would be
considered for osteoporosis risk assessment and screening, and because we could adjust for
hormone use in our multivariable analysis. Women were excluded if they had ever taken an
osteoporosis treatment agent (bisphosphonate, selective estrogen receptor modulator,
calcitonin, or teriparatide) or prescription vitamin D or vitamin D derivative, had a
contraindication to DXA bone density testing, weighed greater than 305 lb, or could not
provide blood for laboratory testing. The research protocol was reviewed and approved by
the Institutional Review Board of the University of North Carolina and the UNC Clinical
Translational Research Center. Informed consent was obtained from all participants at the
time of the study visit.
Measurements
Participants were instructed to fast and to void no more than once after midnight before
attending a morning study visit in the UNC Clinical Translational Research Center. All
blood and urine was collected before 10 a.m. Specimen collection and bone imaging were
completed while the participants were fasting.
Areal bone density measures—Bone mineral density was measured at the femoral
neck, total hip, lumbar spine (L1–L4), and distal radius in all participants by a trained and
certified radiologic technologist using DXA (Hologic Discovery densitometer, Hologic, Inc.,
Bedford, MA). The technician was blinded regarding the specific study hypotheses. Quality
control was maintained by daily scanning of an anthropomorphic spine phantom. The
coefficient of variation for the densitometer is 0.6% and the reference limits for variation are
±1.5%. In vivo precision was not measured because the State of North Carolina Department
of Environment, Health and Safety does not allow performance of DXA on healthy
volunteers for the purpose of precision testing unless it is written as part of a protocol. DXA
results were recorded in grams per square centimeter, and as T-scores ([BMD of participant
– mean BMD of reference population]/SD of BMD of reference population) based on
Hologic reference norms for white and nonwhite women for the lumbar spine, total hip,
femoral neck and distal radius. In accordance with World Health Organization diagnostic
criteria, patients were considered to have osteoporosis if their T-score was −2.5 or below at
any central (spine or hip) anatomical site [10]. A research radiologist (JBR) in the UNC
Department of Radiology reviewed the DXA reports.
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Peripheral QCT measures—We included pQCT imaging at the distal radius because of
the high concentration of trabecular bone at the 4% site, which would allow more sensitive
measurements of bone density changes in response to hormonal influences compared to
DXA. We measured total and trabecular cross-sectional area (mm2) and volumetric bone
density (mg/cm3) at the ultradistal radius by pQCT using an XCT2000 scanner (Stratec,
Orthometrix). Total and cortical area and volumetric density were also assessed at the 33%
distal radius. These sites were chosen according to the 2007 International Society of Clinical
Densitometry Official Positions [11] that recommend scan slices at the 4% site, which
contains up to 80% trabecular bone [12], and a shaft location (15–65% of radius length)
consisting predominantly of cortical bone. Based on an analysis of the last 140 phantom
scans performed on the XCT2000 sn-91255 at UNC between January 31, 2007 and January
14, 2010, the accuracy was −0.20% for measures of trabecular bone density (analysis by
Dan Schiferl, Bone Diagnostic Inc., January 22, 2010). In addition, as a measure of
precision, the standard deviation of the same scans was 1.67 mg/cm3.
Biochemical analyses—Samples of fasting serum were centrifuged within 3 h of
collection and refrigerated before submission to an on-site laboratory. On the day of the
study visit, FSH, luteinizing hormone (LH), and E2≥20 pg/ml were measured using
chemiluminescence-based immunoassays (OrthoClinical Diagnostics, Raritan, NJ), and
albumin was measured using a bromocresol green spectrophotometric method
(OrthoClinical Diagnostics, Raritan, NJ). The remaining serum was frozen in aliquots at
−30°C for short-term storage and −80°C for long-term storage for additional testing. One
sample which had an FSH >200 mIU/ml required quantification using an immunoenzymatic
assay (Beckman-Coulter, Inc, Brea, CA). E2 concentrations below 20 pg/ml were measured
with one of two assays: (1) a no-extraction double antibody 125I RIA (Siemens, Los
Angeles, CA), performed at the Research Triangle Institute International Laboratory of
Reproductive and Endocrine Toxicology (Research Triangle Park, NC) for 12 samples, or
(2) liquid chromatography, tandem mass spectrometry performed at Esoterix, Inc.
Endocrinology Laboratory Services for 99 samples. We used bioavailable (free or associated
with albumin in the circulation) sex steroid concentrations because they better reflect the
fractions of these factors available to tissues [13]. The bioavailable E2 (bio E2)
concentration was calculated by multiplying the total E2 by the fraction that was non-SHBG
bound as per Khosla et al. [13]. Bioavailable testosterone (bio T, differential precipitation
method) was measured and reported by Mayo Medical Laboratories.
Assays for the following were also conducted: thyroid stimulating hormone (TSH,
(OrthoClinical Diagnostics, Raritan, NJ), free thyroxine (OrthoClinical Diagnostics, Raritan,
NJ), parathyroid hormone (PTH, Roche Diagnostics, Corp, Indianopolis, IN), sex-hormone
binding globulin (SHBG, Siemens Healthcare Diagnostics, Deerfield, IL),
dehydroepiandrosterone sulfate (DHEAS, Siemens Health-care Diagnostics, Deerfield, IL),
bone specific alkaline phosphatase (BSAP, Beckman-Coulter, Inc., Brea, CA), and serum
25-OH vitamin D (liquid chromatography tandem-mass spectrometry, Mayo Medical
Laboratories).
Other independent variables—Demographic information and risk factors for
osteoporosis and fracture (including age, years since menopause, use of hormone therapy,
hysterectomy with or without ovariectomy) were recorded by trained research assistants.
Anthropometric measurements were taken by a research nurse in the UNC Clinical
Translational Research Center.
Gourlay et al. Page 4














Descriptive statistics—In the univariate analysis, means and standard deviations were
calculated for demographic and anthropomorphic measures, hormonal variables, and DXA
and pQCT measures. Spearman rank correlations, which are not sensitive to outliers, were
used to analyze unadjusted relationships among FSH, bio E2, and other independent
variables and outcomes.
Multivariable analysis—Separate multiple linear regression models were constructed for
these dependent variables: areal BMD (g/cm2) at the lumbar spine, femoral neck and total
hip, total bone area (mm2) and total volumetric bone density (mg/cm3) at the 4% and 33%
distal radius, trabecular area and volumetric density at the ultradistal radius, and cortical area
and volumetric density at the 33% distal radius. These independent variables were initially
considered for each model: age, weight, race (nonwhite vs. white), years since menopause,
ever use of hormone therapy, FSH, bio E2, bio T, LH, SHBG, DHEA-S, TSH, PTH, BSAP,
and serum 25-OH vitamin D. We used simple (single variable) linear regression to select
into the multivariable models for BMD outcomes those independent variables with at least
one p value for unadjusted associations with the BMD outcomes less than 0.05; we repeated
this variable selection process for the pQCT outcomes. To test for multi-collinearity of the
explanatory variables in the models, variance inflation factors were calculated and ranged
from 1.08 (BSAP) to 3.19 (FSH) [VIF <10 indicates no extreme multi-collinearity]. Results
from the models were expressed in beta coefficients, which represent the mean change in the
dependent variable for a 1 unit change in the independent variable, adjusted for the other
covariates. For example, a beta coefficient (β) of −0.0003 for FSH vs. femoral neck BMD
would mean for a 1-unit (1 mIU/ml) increase in FSH, the femoral neck BMD was 0.0003 g/
cm2 lower, adjusted for the other independent variables in the model. Age, weight, and years
since menopause were divided by 10 before inclusion in the models; after this
transformation, a β of −0.005 meant for a 10-year increase in age, the femoral neck BMD
was 0.005 g/cm2 lower, adjusted for the other independent variables. Race was coded as 0=
nonwhite, 1=white; thus, β<0 for the race variable meant that bone density was lower in
white women compared with nonwhite women. Statistical analyses were performed using
the Stata SE 9.2 software [14].
We used the Bonferroni correction for adjusting the significance levels for p values to
correct for multiple comparisons [15]. Using this method, p values ≤0.0125 and ≤0.00625
were considered statistically significant for DXA bone density outcomes (four) and pQCT
outcomes (eight), respectively. p values greater than these thresholds but less than 0.05 were
considered nearly significant.
Sample size calculations—The planned sample size of 111 women provided 80%
power to detect a (population) correlation coefficient between two continuous-scaled
variables as small (in absolute terms) as 0.26 with two-sided tests of statistical significance
at the 0.05 level (e.g., a correlation between FSH and trabecular volumetric BMD of −0.26).
In comparison, an unadjusted r value of 0.44 was found in a correlation of bioavailable
estradiol and trabecular volumetric bone mineral density in a population-based cohort of
women aged 40–59 years [16]. For a correlation of this magnitude, the study provided 99%
power.
Results
Study population, anthropomorphic, FSH, and sex steroid measures
Participants had a mean age of 57.5 years, were predominantly white (80.0%), and were
overweight on average (mean weight 79.7 kg, mean BMI 29.6; Table 1). Fifty-two percent
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of the women had used hormone therapy, including 16 (14.4%) current users. Mean FSH
was 59.4 mIU/ml with values varying over a wide range (1.6–270 mIU/mL). FSH was
significantly higher in normal weight women compared with overweight and obese women
(80.0 vs. 49.5 mIU/ml, p<0.001) and in past/never estrogen users vs. current estrogen users
(62.4 vs. 41.3 mIU/ml, p=0.02). Similarly, bio E2 (0.76 vs. 1.11 ng/dl, p=0.45) and bio T
(2.35 vs. 3.06 ng/dl, p=0.29) were lower in normal weight women compared with heavier
women, but these differences did not reach statistical significance. Mean BMD was in the
normal range (T-score≥−1 at all sites).
Unadjusted Spearman's correlations
Rank correlations among selected patient-related factors and hormonal variables are shown
in Table 2. FSH was strongly correlated with LH (r=0.81, p<0.001) and inversely correlated
with weight (r=−0.57, p<0.001, Fig. 1a) and bio E2 (r=−0.50, p<0.001). White women
weighed less than nonwhite women (r=−0.35, p<0.001). Weight was moderately correlated
with bio E2 (r=0.42, p< 0.001) and less strongly with bio T (p=0.25, p=0.007).
FSH was inversely correlated with areal bone density sites (r=−0.39 to −0.21, p≤0.028 for
all sites; Table 2, Fig. 1b). Weight (r=0.29 to 0.60, p≤0.0024 for all sites) and race (r=−0.44
to −0.35, p≤0.0002 for all sites) were moderately correlated with areal BMD.
Correlations with pQCT measures are shown in Table 3. FSH was inversely correlated with
total (r=−0.22, p=0.02) and trabecular (r=−0.27, p=0.005) vBMD at the ultradistal radius
[Figs. 1c and d], and with total bone area (r=−0.23, p=0.02) and cortical area (r=−0.21,
p=0.04) at the 33% site. Weight showed statistically significant associations with the same
pQCT sites as FSH. Bio E2 and bio T showed statistically significant associations with total
and trabecular vBMD values at the ultradistal site. Race was associated with total vBMD (r=
−0.21, p=0.03) at the ultradistal site and was moderately and inversely correlated with total
bone area (r=−0.31, p=0.001) and cortical area (r=−0.39, p<0.001) at the 33% distal radius.
Multivariable analysis with areal BMD outcomes
After adjustment for the other independent variables in the models, FSH, bio E2, and bio T
were not significantly associated with areal BMD at any site. Weight was independently
associated with BMD of the lumbar spine (β=0.033, p=0.007), femoral neck (β=0.028,
p<0.001), and total hip (β=0.027, p<0.001); this indicates that for each 10 kg increase in
weight, areal BMD was 0.027– 0.033 g/cm2 greater. Race was independently associated
with lumbar spine (β=−0.074, p=0.008), femoral neck (β=−0.108, p<0.001), total hip (β=
−0.087, p=0.001), and distal radial (β=−0.057, p<0.001) BMD (Table 4). Age (β=−0.043,
p=0.003) and BSAP (β=−0.004, p=0.001) were significantly associated with distal radial
BMD.
Multivariable analysis with pQCT outcomes at the 4% and 33% distal radius
Compared to the findings for areal BMD at weight bearing sites, fewer significant
associations were found for distal radial pQCT outcomes. In the adjusted models, no
hormonal variable showed any significant associations with pQCT outcomes (Tables 5 and
6). Only race was significantly associated with cortical area (β=−7.822, p= 0.001) at the
33% distal radius. Several associations were near statistical significance (0.00625<p<0.05):
at the 4% site, weight (β=5.268, p=0.045) and bio T (β=−3.553, p= 0.011) were associated
with total bone area and FSH (β=−0.411, p=0.020) and LH (β=0.725, p=0.033) were
associated with trabecular vBMD. At the 33% site, race (β=−7.836, p=0.026) was associated
with total bone area and age (β=−55.790, p=0.039), bio E2 (β=8.421, p= 0.048), and BSAP
(β=−5.936, p=0.014) were associated with total vBMD. Age, weight, and BSAP were
associated with cortical area, and bio E2 and BSAP were associated with cortical vBMD at
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the 33% site. Other analyzed measures including years since menopause, ever use of
hormone therapy, TSH, PTH, SHBG, DHEAS, and 25-OH vitamin D showed no statistically
significant nor near significant associations with distal radial pQCT measures in the adjusted
models.
Results of a post hoc sensitivity analysis for FSH vs. BMD and pQCT outcomes that omitted
the observation with outlying FSH value shown in Fig. 1 did not qualitatively differ from the
main analyses based on 111 postmenopausal women. When FSH and bio E2 were removed
from the models, the associations for weight and race reported above remained statistically
significant.
Discussion
This cross-sectional study of postmenopausal women aged 50–64 years recruited from
primary care practices or the community found insufficient evidence to support an
association between FSH or bio E2 and bone density measured by DXA or by distal radial
pQCT after adjustment for patient-related factors and other hormonal variables. The
correlational analysis showed that FSH concentrations were higher and bio E2
concentrations were lower on average in thin, white women compared with heavier
nonwhite women, and the former group had lower bone density. However, the multivariable
analysis showed that weight and race were independently associated with areal BMD, while
FSH and bio E2 were not significant determinants. This suggests that the inverse
relationship between FSH and BMD was mostly due to confounding variables. Race was the
only factor showing a statistically significant association with a pQCT outcome (cortical
area at 33% distal radius). This indicates a less important role of weight in determining
pQCT outcomes at a non-weight-bearing site compared to areal BMD at weight-bearing
sites.
FSH would warrant consideration as a screening biomarker if high concentrations were
consistently associated with lower bone strength, or if it was found to be a more robust
marker than easily measurable patient-related factors such as weight. Past longitudinal
studies have shown associations between FSH and bone density loss in pre- and
postmenopausal study populations. Riggs et al. found that in postmenopausal women,
several significant correlations existed between bio E2, bio T, and FSH vs. cortical and
trabecular bone loss in the distal radius, distal tibia, and lumbar spine [5]. While their
analysis also included IGF, C-telopeptide, and propeptide of type I collagen, it did not
account for body weight. Sowers et al., following pre- and early perimenopausal women into
the menopausal transition, found that lumbar spine and hip BMD losses were most strongly
related to the interaction between initial FSH concentration and longitudinal FSH change
and not to sex steroid concentrations, after adjustment for BMI [4]. We chose to include
weight rather than BMI in our models because Robbins et al. found weight alone to be a
much better predictor of BMD than BMI [17]. We acknowledge that a longitudinal study
might show a different relationship between FSH and bone loss. Also, because FSH
concentrations rise significantly in the perimenopausal period then plateau after menopause
[18], associations between FSH and low bone density may be different in perimenopausal
women compared to our postmenopausal study population.
Our data suggest that loading was more important than hormonal effects at weight-bearing
sites in younger postmenopausal women. Weight is known to be a key predictor of
osteoporosis [19–22] and bone loss [23–25] in postmenopausal women. In their meta-
analysis of the WHI, EPIDOS, and CHS databases, Robbins et al. speculated that increased
weight promoted load induced changes in the skeleton [17]. Increased mechanical loading of
bone is associated with increased bone strength [26]. Accordingly, Beck et al. found femur
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BMD and geometric strength to be greater in overweight and obese postmenopausal women
aged 50–79 compared with normal weight and underweight in a cross-sectional analysis, and
the heavier patient group reported a history of fewer fractures at the hip and other central
body sites, but not in the extremities [27]. Increased weight is also associated with increased
estrogen production by aromatization in adipose tissue [28] and lower concentrations of
SHBG [29], both of which increase the bioavailable fraction of estrogen. In our study,
weight did not predict cortical or trabecular bone volumetric mass in the radius, a site where
body weight should contribute less to the loading environment. The lean mass and fat mass
components of weight may be relevant factors, but they could not be included in our
analysis because of collinearity.
Race was significantly associated with areal BMD at most weight bearing sites, and with
cortical area at the 33% radius site. Mean bone density is greater in black women than in
white women in the US general population [30]. The nonwhite group in our study
population comprised of 27 black women and four women of other races, meaning that the
race comparison was mostly black vs. white in our analysis. As such, our results were
consistent with population norms for bone density by race which suggest that genetic factors
underlie cortical size.
Our study has several limitations. As in all cross-sectional analyses, we could only show
associations between hormonal measures and bone density; the results do not demonstrate
cause–effect relationships. Importantly, the results do not apply to the rate of bone loss,
which could cause marked changes in bone density in subsequent decades after this early
stage of the postmenopausal period. Our study population was small, but comparable in size
to past cross-sectional studies of associations between hormonal factors and pQCT measures
of bone. We used a Bonferroni adjustment to adjust for multiple hypothesis testing. Because
this approach is conservative and may increase type II error (actual association is not
detected) [15,31], the associations we found with near statistical significance might become
significant in a larger study. Factors such as inhibins and serotonin were not included in our
analysis, and might have altered our results.
In conclusion, our multivariable analysis did not find a significant association between FSH
or bio E2 and bone density measures by DXA or pQCT in postmenopausal women aged 50–
64 years. Instead, the easily obtainable measures of weight and race were more useful than
hormonal factors as clinical indicators of bone density and should be included in analyses of
potential bone biomarkers.
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a Scatterplot of weight vs. serum FSH. b Scatterplot of femoral neck areal BMD vs. serum
FSH. c Scatterplot of total vBMD at ultradistal radius vs. serum FSH. d Scatterplot of
trabecular vBMD at ultradistal radius vs. serum FSH
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Table 1
Subject characteristics (n=111)
Characteristic Mean (SD) or n (%)
Age, years 57.5 (3.7)
Weight, kg 79.7 (20.1)
 Range 46.8–137.2
BMI (kg/m2) 29.6 (74)
 Range 18.7–49.2
Ethnicity/race, n (%)
 White 80 (72.1)
 Black 27 (24.3)
 Other 4 (3.6)
Years since menopause 11.3 (9.0)
Had a hysterectomy, n (%) 38 (43.7)
Ever use of hormone therapy, n (%) 58 (52.3)
Current use of hormone therapy, n (%) 16 (14.4)
FSH, mIU/ml 59.4 (34.8)
 Range 1.6–270
Total serum E2, pg/mL 13.0 (28.8)
Bio E2, ng/dl 0.99 (2.25)
 Range 0–19.55
Bio T, ng/dl 2.54 (2.71)
SHBG, nmol/L 47.8 (32.8)
Lumbar spine DXA
 BMD, g/cm2 1.014 (0.143)
 T-score −0.49 (1.22)
 Z-score 0.79 (1.23)
Femoral neck DXA
 BMD, g/cm2 0.772 (0.134)
 T-score −0.87 (1.02)
 Z-score 0.23 (0.98)
Total hip DXA
 BMD, g/cm2 0.889 (0.135)
 T-score −0.58 (0.94)
 Z-score 0.20 (0.92)
Distal radius DXA
 BMD, g/cm2 0.702 (0.062)
 T-score 0.13 (1.04)
Normal values for postmenopausal women: FSH 21.5–131 mIU/ml, total E2 <15 pg/ml, bio E2 not available from reference laboratories, bio T not
established, SHBG 20–130 nmol/L
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Table 4
Beta coefficients for independent associations in adjusted models of BMD (n= 111)
Independent variablea Beta coefficient (SE)
Lumbar spine BMD Femoral neck BMD Total hip BMD Distal radius BMD
Age, years −0.003 (0.031) −0.054 (0.028) −0.033 (0.029) −0.0428 (0.014)*
Weight, kg 0.033 (0.007)* 0.028 (0.006)* 0.027 (0.006)* 0.005 (0.003)
Race −0.074 (0.028)* −0.108 (0.025)* −0.087 (0.026)* −0.057 (0.012)*
FSH, mIU/ml 0.00001 (0.001) −0.0003 (0.001) −0.0006 (0.0005) −0.0002 (0.0003)
Bioavailable estradiol, ng/dl 0.007 (0.005) 0.002 (0.005) 0.002 (0.005) 0.003 (0.002)
Bioavailable testosterone, ng/dL 0.003 (0.004) −0.002 (0.003) 0.00006 (0.003) 0.002 (0.002)
LH, mIU/ml 0.0001 (0.001) 0.001 (0.001) 0.001 (0.001) 0.0008 (0.0005)
TSH, microIU/ml −0.008 (0.009) −0.007 (0.008) −0.011 (0.008) 0.001 (0.004)
SHBG, nmol/L −0.0002 (0.0004) −0.0006 (0.0004) −0.0007 (0.0004) −0.00001 (0.0002)
BSAP 0.005 (0.003) −0.004 (0.002) −0.003 (0.003) −0.004 (0.001)*




Age and weight divided by 10; other independent variables were ever use of hormone therapy, years since menopause, PTH, DHEAS, and 25-OH
vitamin D, all nonsignificant
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Table 5
Beta coefficients for independent associations in adjusted models of pQCT measures at
the 4% (ultradistal) radius
Independent variablea Beta coefficient (SE)
Total bone area Trabecular vBMD
Age, years 0.346 (11.298) −9.752 (9.787)
Weight, kg 5.268 (2.597)* 3.938 (2.250)
Race −0.698 (10.103) −10.998 (8.752)
FSH, mIU/ml 0.185 (0.200) −0.411 (0.173)*
Bioavailable estradiol, ng/dl 0.337 (1.840) −0.609 (1.594)
Bioavailable testosterone, ng/dL −3.553 (1.378)* 0.784 (1.194)
LH, mIU/ml 0.010 (0.386) 0.725 (0.334)*
TSH, microIU/ml −3.199 (3.167) −.338 (2.743)
SHBG, nmol/L −0.168 (0.162) −0.116 (0.140)
BSAP, ug/L −0.677 (0.987) −0.770 (0.855)
DHEAS, mcg/dL −0.037 (0.094) 0.153 (0.082)
SE standard error
a
Age and weight divided by 10; other independent variables were ever use of hormone therapy, years since menopause, PTH, and 25-OH vitamin
D, all nonsignificant. All results nonsignificant for total bone volumetric BMD and trabecular area at the 4% site (data not shown).
*
0.00625<p<0.05
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Table 6
Beta coefficients for independent associations in adjusted models of pQCT measures at
the 33% distal radius
Independent variable* Beta coefficient (SE)
Total bone area Total vBMD Cortical area Cortical vBMD
Age, years −2.222 (3.892) −55.790 (26.642)* −6.045 (2.484)* −10.874 (8.836)
Weight, kg 0.983 (0.864) 2.681 (5.914) 1.165 (0.551)* −1.308 (1.961)
Race −7.836 (3.459)* −18.070 (23.677) −7.822 (2.207)** −5.904 (7.853)
FSH, mIU/ml −0.027 (0.067) −0.010 (0.457) −0.019 (0.043) −0.0109 (0.152)
Bioavailable estradiol, ng/dl −0.39 (0.613) 8.421 (4.200)* 0.237 (0.391) 3.327 (1.393)*
Bioavailable testosterone, ng/dL −0.35 (0.457) 2.575 (3.127) −0.104 (0.291) 0.655 (1.037)
LH, mIU/ml −0.063 (0.128) 1.118 (0.880) 0.037 (0.0820) 0.219 (0.292)
TSH, microIU/ml −1.924 (1.057) 8.361 (7.234) −0.815 (0.674) 0.723 (2.399)
SHBG, nmol/L −0.032 (0.055) .080 (0.374) −.022 (0.035) 0.141 (0.124)
BSAP, ug/L −0.098 (0.345) −5.936 (2.360)* −0.459 (0.220)* −1.806 (0.783)*
DHEAS, mcg/dL −0.023 (0.032) 0.119 (0.218) −0.008 (0.020) 0.058 (0.072)






Age and weight divided by 10; other independent variables were years since menopause, PTH, and 25-OH vitamin D, all nonsignificant
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